Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 12, 1998, Pages 2345-2381

  Robarge, Kirk D ^a   Dina, Michael S ^a   Somers, Todd C ^a   Lee, Arthur ^a   Rawson, Thomas E ^a   Olivero, Alan G ^a   Tischler, Maureen H ^a   Webb II, Robert R ^a   Weese, Kenneth J ^a   Aliagas, Ignacio ^a   Blackburn, Brent K ^a,b  

^a GENENTECH INC   (United States)

^b CV THERAPEUTICS INC   (United States)

Author keywords

Tricyclic GPIIb IIIa antagonists

Indexed keywords

BENZODIAZEPINE DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

EID: 13044263877     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)80013-8     Document Type: Article

References (51)

1. (a) The majority of the analogues, whose preparation and in vitro evaluation are described in this study, are novel tricyclic GPIIb/IIIa antagonists. However, the preparation and in vitro evaluation of one novel tetracyclic GPIIb/IIIa antagonist is also included,
2. (b) A portion of the work described herein, as well as SAR of additional tricyclic IIbIIIa antagonists containing a nonoptimized arginine surrogate, was presented at the 209th National ACS Convention, Anaheim, CA.; Abstract 229, MEDI.
3. Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. Blood 1988, 71, 831.
4. Peerschke, E. I.; Zucker, M. B.; Grant, R. A.; Egan, J. J.; Johnson, M. M. Blood 1980, 55, 841.
5. Falk, E. Circulation 1985, 71, 699.
6. Coller, B. S. New Engl. J. Med. 1990, 322, 33.
7. Cadroy, Y.; Harker, L. A. In Cardiovascular Pharmacology, 3rd ed.; Antonaccio, M., Ed.; Raven Press: New York, 1990; pp 515-539.
8. Scharf, R. E.; Harker, L. A. Blut 1987, 55 (3), 131.
9. Zablocki, J. A.; Rao, S. N.; Baron, D. A.; Flynn, D. L.; Nicholoson, N. J.; Feigen, L. P. Curr. Pharm. Des. 1995, 1, 533.
10. Farrell, D. H.; Thiagarajan, P. J. Biol. Chem. 1994, 269, 226.
11. Zaidi, T. N.; McIntire, L. V.; Farrell, D. H.; Thiagarajan, P. Blood, 1996, 88, 2967.
12. Weller, T.; Alig, L.; Müller, M. H.; Kouns, W. C.; Steiner, B. Drugs Future 1994, 19, 461. For recent reviews of nonpeptidal GPIIb/IIIa antagonists see Refs. 11-14.
13. Jakubowski, J. A.; Smith, G. F.; Sall, D. J. Ann. Rept. Med. Chem. 1992, 27, 99.
14. Blackburn, B. K.; Gadek, T. R. Ann. Rept. Med. Chem. 1993, 28, 79.
15. Cook, N. S.; Kottirsch, G.; Zerwes, H. G. Drugs Future 1994, 19, 135.
16. McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischler, M.; Webb, II R. R.; Venuti, M. C. J. Am. Chem. Soc. 1994, 116, 5077. The synthesis of compounds 1a, 16, and 17 can be found in the supplementary material.
17. A Receptor, U.S. Patent 5,663,166 1997. For preparation of 18, see page 219 of U.S. Patent 5,663,166. In the base mediated ring closure to yield 19, cesium carbonate (1.2 equiv., DMF, rt) was also a suitable base. The procedure to prepare 19 using sodium hydride to promote 7-member ring formation is described on page 220 of U.S. Patent 5,663,166.
18. Austel, V.; Himmelsbach, F.; Müller, T. Drugs Future 1994, 19, 757.
19. Lefkovits, J.; Plow, E. F.; Topol, E. J. New Engl. J. Med. 1995, 332, 1553.
20. Stilz, H. U.; Jablonka, B.; Just, M.; Knolle, J.; Paulus, E. F.; Zoller, G. J. Med. Chem. 1996, 39, 2118.
21. Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzmann, L.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S.; Nicholson, N.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. J. Med. Chem. 1993, 36, 1811.
22. Alig, L.; Edenhofer, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trzeciak, A.; Weller, T. J. Med. Chem. 1992, 35, 4393.
23. Kloczewiak, M.; Timmons, S.; Bednarek, M. A.; Sakon, M.; Hawinger, J. Biochemistry 1989, 28, 2915.
24. Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. L.; Chan, K. S.; Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; Tom, J. Y. K.; Burnier, J. P. J. Med. Chem. 1992, 35, 2040.
25. Kopple, K. D.; Baures, P. W.; Bean, J. W.; D'Ambrosio, C. A.; Hughes, J. L.; Peishoff, C. E.; Eggleston, D. S. J. Am. Chem. Soc. 1992, 114, 9615.
26. Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calvo, R.; D'Ambrosio, C. A.; Eggleston, D. S.; Hwang, S. M.; Kline, T. P.; Koster, P. F.; Nichols, A.; Powers, D.; Romoff, T.; Samanan, J. M.; Stadel, J.; Vasko, J. A.; Kopple, K. D. J. Med. Chem. 1992, 35, 3962.
27. Bach, II A. C.; Eyermann, C. J.; Gross, J. D.; Bower, M. J.; Harlow, R. L.; Weber, P. C.; DeGrado, W. F. J. Am. Chem. Soc. 1994, 116, 3207.
28. Hann, M. M.; Carter, B.; Kitchin, J.; Ward, P.; Pipe, A.; Broomhead, J.; Hornby, E.; Foster, M.; Perry C. Molecular Recognition: Chemical and Biochemical Problems II; Roberts, S. M., Ed; Special Publication No.111; The Royal Society of Chemistry: Cambridge, 1992.
29. U.S. Patent 5,705,890 1998. The tricyclic inhibitors were designed to be out of the scope covered in PCT/US92/05463 (WO 93/00095) titled Bicyclic Fibrinogen Antagonists.
30. Askew, B. C.; McIntyre, C. J.; Hunt, C.A.; Claremon, D. A.; Gould, R. J., Lynch, R. J., Armstrong, D. J. Bioorg. Med. Chem. Lett. 1995, 5, 475.
31. Egbertson, M. S.; Naylor, A. M.; Hartman, G. D.; Cook, J. J.; Gould, R. J.; Holahan, M. A.; Lynch, Jr. J. J.; Lynch, R. J.; Stranieri, M. T.; Vassallo, L. M. Bioorg. Med. Chem. Lett. 1994, 4, 1835.
32. Naylor, A. M.; Egbertson, M. S.; Vassallo, L. M.; Birchenough, L. A.; Zhang, G. X.; Gould, R. J.; Hartman, G. D. Bioorg. Med. Chem. Lett. 1994, 4, 1841.
33. Eldred, C. D.; Evans, B.; Hindley, S.; Judkins, B. D.; Kelley, H. A.; Kitchin, J.; Lumley, P.; Porter, B.; Ross, B. C.; Smith, K. J.; Taylor, N. R.; Wheatcroft, J. R. J. Med. Chem. 1994, 37, 3882.
34. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. J. Am. Chem. Soc. 1993, 115, 8861.
35. Jones, G. H.; Venuti, M. C.; Alvarez, R.; Bruno, J. J.; Berks, A. H.; Prince, A. J. Med. Chem. 1987, 30, 295.
36. Venuti, M. C.; Jones, G. H.; Alvarez, R.; Bruno, J. J. J. Med. Chem. 1987, 30, 303.
37. (a) TCI supplies > 98% purity N-methyl isatoic anhydride which provides products in much greater purity and yield than the use of technical grade N-methyl isatoic anhydride.
38. (b) 1.0 M KPhos buffer (pH 7) was prepared by mixing 1.0 M potassium phosphate monobasic and 1.0 M potassium phosphate dibasic until pH 7.0 (approximately 1:1.2 ratio).
39. 5-Nitro isatoic anhydride is available from Trans World Chemical.
40. Watjen, F.; Baker, R.; Engelstoff, M.; Herbert, R.; MacLeod, A.; Knight, A.; Merchant, K.; Moseley, J.; Saunders, J.; Swain, C. J.; Wong, E.; Springer, J. P. J. Med. Chem. 1989, 32, 2282.
41. Bock, M. G.; DiPardo, R. M.; Pitzenberger, S. M.; Homnick, C. F.; Springer, J. P.; Freidinger, R. M. J. Org. Chem. 1987, 52, 1644.
42. Freidinger, R. M. EP 0 519 678 A2.
43. Duncia, J. V.; Pierce, M. E.; Santella, III J. B. J. Org. Chem. 1991, 56, 2395.
44. Blackburn, B. K.; Lee, A.; Baier, M.; Kohl, B.; Olivero, A. G.; Matamoros, R.; Robarge, K. D.; McDowell, R. S. J. Med. Chem. 1997, 40, 717.
45. Tsuji, J. Organic Synthesis with Palladium Compounds; Springer-Verlag: Berlin, 1980.
46. Heck, R. F. Palladium Reagents in Organic Synthesis; Academic Press: London, 1985.
47. For a review of thionation reactions with Lawesson's reagent, see Cava, M. P.; Levinson, M. I. Tetrahedron 1985, 41, 5061.
48. Foloppe, M. P.; Rault, S.; Robba, M. Tetrahedron Lett. 1992, 33, 2803.
49. Baxter, S. L.; Bradshaw, J. S. J. Org. Chem. 1981, 46, 831.
50. Presented at the 214th National ACS Convention, Las Vegas, Nevada. Abstract 27, MEDI.
51. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian 94, Revision B.3 ed. Pittsburgh PA, 1995.